Quick Answer
bioAffinity Technologies, Inc. reported Cash and Equivalents of $6.45 million for fiscal year 2025.
bioAffinity Technologies, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.45M | +483.5% |
| 2024 | $1.11M | -60.8% |
| 2023 | $2.82M | -75.3% |
| 2022 | $11.41M | +738.9% |
| 2021 | $1.36M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.67M | +913.7% | +855.3% |
| June 30, 2025 | $802.8K | +0.2% | +80.5% |
| March 31, 2025 | $444.7K | -81.9% | -59.8% |
| December 31, 2024 | $1.11M | -60.8% | +46.1% |
| September 30, 2024 | $756.6K | -83.2% | -5.6% |
| June 30, 2024 | $801.3K | -90.3% | -67.3% |
| March 31, 2024 | $2.45M | -74.9% | -13.1% |
| December 31, 2023 | $2.82M | -75.3% | -37.4% |
- bioAffinity Technologies, Inc. showed an increase of +483.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, bioAffinity Technologies, Inc.’s cash and equivalents has grown by 374.0% (from $1.36 million to $6.45 million).
- The most recent figure is from bioAffinity Technologies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: